Bucci-Rechtweg, Christina

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research

Bone health and osteoporosis researchBone health and treatments

Cited by 700

Fracture risk and zoledronic acid therapy in men with osteoporosis

Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 359

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., Collette, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., & Reginster, J.-Y. (2013) · Rheumatology

Bone health and osteoporosis researchBone health and treatments

Cited by 19

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Sambrook, P. N., Roux, C., Devogelaer, J.-P., Saag, K., Lau, C.-S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012) · Bone

Bone health and osteoporosis researchBone health and treatments

Cited by 3